Heart Disease and Stroke Risk Profile
Use
This test provides an assessment of the risk factors associated with heart disease and stroke, including the measurement of biomarkers such as C-reactive protein, cardiac; lipoprotein (a); fibrinogen activity; and von Willebrand factor antigen. These biomarkers are involved in inflammatory processes and coagulation pathways, which are critical in the pathogenesis of cardiovascular diseases. The test aids healthcare providers in identifying patients at increased risk for heart disease and stroke and guiding therapeutic interventions to mitigate these risks.
Special Instructions
State patient's sex on the request form. If the patient's hematocrit exceeds 55%, adjust the volume of citrate in the collection tube. Refer to Coagulation Collection Procedures for directions. It is important to note that citrated plasma samples should be collected by double centrifugation, and specific collection instructions must be followed to ensure proper specimen quality.
Limitations
This test was developed and its performance characteristics determined by Labcorp. However, it has not been cleared or approved by the Food and Drug Administration, which may impact its acceptance in certain clinical scenarios. The test includes measurements performed on serum and plasma samples, and any deviations in specimen collection, handling, or processing may affect the accuracy of the results. Potential analytical interferences or limitations specific to the individual biomarkers may also impact the test outcomes.
Methodology
Other
Biomarkers
LOINC Codes
- 43583-4
- 30522-7
- 3255-7
- 27816-8
Result Turnaround Time
2-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL serum
Minimum Volume
Not provided
Container
Red-top tube or gel-barrier tube
Patient Preparation
Do not draw from an arm with a heparin lock or heparinized catheter.
Storage Instructions
Refrigerate serum.